Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Combination

Glow combination

Also known as GLOW blend

In vitro — evidence level 1 of 4: In-vitro evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A three-peptide mixture with no published study of the combination at any level.

Category
Combination
Highest evidence level identified
In-vitro evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

Glow is not a molecule but a mixture of three unrelated compounds: BPC-157, TB-500, and GHK-Cu. Each acts on a different molecular target, and the pharmacology of the mixture is not the arithmetic sum of the three — co-administration can alter absorption, protein binding, degradation and receptor-level interaction in ways that cannot be predicted from single-agent data. The copper in GHK-Cu additionally introduces a metal-redox variable absent from the other two.

Research areas

  • Combination pharmacology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

None. No published study tests these three together.

Animal evidence

Studies in living non-human animals.

None. No animal study administers this three-way combination.

Human observational evidence

Studies observing people without assigning an intervention.

None. No case series, cohort or registry data.

Clinical-trial evidence

Studies assigning an intervention to human participants.

None. No registered or published trial of the combination exists. Targeted searches pairing each constituent with each other returned only narrative reviews that discuss the compounds separately — never a study of the mixture.

Study limitations

  • The evidence level shown is the floor of the framework and overstates the position. The combination has not been tested at any level, including in vitro. There is no evidence for this mixture, only evidence for its parts.
  • There is no standardised composition. This is a marketing name rather than a defined substance — no monograph, no fixed ratio, no pharmacopoeial standard. One supplier’s product is not another’s, so reproducibility is impossible in principle.
  • Every claim made for it is additive extrapolation from three separate single-agent literatures, each of which is itself dominated by cell and rodent work.
  • TB-500 is a seven-residue fragment, not thymosin beta-4. Claims that migrate from the parent protein’s literature add a second layer of extrapolation on top of the first.
  • An analysis of 6,441 directly-marketed research-grade samples, including all three constituents, found between 41.6 and 71.1 per cent failed basic quality criteria and 15 per cent carried measurable endotoxin.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: The Human Medicines Regulations 2012, regulation 46 — prohibition on sale or supply of an unauthorised medicinal product (opens legislation.gov.uk in a new tab) (legislation.gov.uk)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

No safety data exist for this combination in humans or animals. Single-agent safety data cannot simply be added together: interaction effects, cumulative off-target burden and combined impurity load are all unquantified. The dominant near-term hazard is not peptide pharmacology but product quality — sterility failures and endotoxin in unregulated injectable preparations. GHK-Cu additionally delivers copper, for which no established safe parenteral exposure profile exists in this context.

References